By now, your news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the meds approved for weight loss known as semaglutide (e.g. Ozempic) and tirzepatide (e.g.Mounjaro, Zepbound). Now, there’s a new peptide in town: retatrutide.
Yes, all of these chemicals are technically peptides, and each of them works in a slightly different way, activating different receptors in the body. Semaglutide activates the GLP-1 (glucagon-like peptide-1) receptor, for example. Tirzepatide is considered a dual receptor agonist because it activates the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide).
Already a member? Sign In
Get exclusive workout plans and fitness challenges, 500+ streaming workouts from top trainers, expert nutrition advice, and much more!
